GSA Capital Partners LLP bought a new stake in Assertio Holdings, Inc. (NASDAQ:ASRT – Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 149,968 shares of the company’s stock, valued at approximately $177,000. GSA Capital Partners LLP owned about 0.16% of Assertio at the end of the most recent quarter.
A number of other large investors also recently bought and sold shares of the company. Point72 DIFC Ltd acquired a new position in shares of Assertio during the 2nd quarter worth $40,000. Thurston Springer Miller Herd & Titak Inc. lifted its holdings in shares of Assertio by 304.0% in the third quarter. Thurston Springer Miller Herd & Titak Inc. now owns 50,500 shares of the company’s stock valued at $60,000 after purchasing an additional 38,000 shares in the last quarter. Marshall Wace LLP purchased a new position in shares of Assertio during the 2nd quarter worth approximately $70,000. Los Angeles Capital Management LLC acquired a new stake in Assertio during the 2nd quarter valued at $77,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Assertio during the second quarter worth about $149,000. Hedge funds and other institutional investors own 48.96% of the company’s stock.
Insider Transactions at Assertio
In other news, Director Heather L. Mason bought 75,000 shares of the business’s stock in a transaction on Monday, November 18th. The stock was purchased at an average cost of $0.80 per share, for a total transaction of $60,000.00. Following the completion of the transaction, the director now directly owns 287,650 shares of the company’s stock, valued at approximately $230,120. This trade represents a 35.27 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 3.20% of the company’s stock.
Assertio Trading Down 2.6 %
Assertio (NASDAQ:ASRT – Get Free Report) last released its quarterly earnings data on Monday, November 11th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.02. The firm had revenue of $29.20 million for the quarter, compared to analyst estimates of $29.29 million. Assertio had a negative net margin of 54.46% and a positive return on equity of 3.79%. During the same quarter in the prior year, the business earned ($0.01) earnings per share. On average, analysts predict that Assertio Holdings, Inc. will post -0.17 EPS for the current year.
Analyst Upgrades and Downgrades
Separately, StockNews.com upgraded Assertio from a “hold” rating to a “buy” rating in a research note on Wednesday, November 13th.
Get Our Latest Analysis on Assertio
Assertio Profile
Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.
See Also
- Five stocks we like better than Assertio
- The Significance of Brokerage Rankings in Stock Selection
- Disney’s Magic Strategy: Reinventing the House of Mouse
- Health Care Stocks Explained: Why You Might Want to Invest
- Volatility in Semis? 3 Stable Alternatives to NVIDIA and SMCI
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
Want to see what other hedge funds are holding ASRT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Assertio Holdings, Inc. (NASDAQ:ASRT – Free Report).
Receive News & Ratings for Assertio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assertio and related companies with MarketBeat.com's FREE daily email newsletter.